Generic Name: alpelisib
Brand Name: Piqray
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Therapeutic Area: Advanced or Metastatic Breast Cancer.
Indications: Piqray (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.
Manufacturer Requested Reimbursement Criteria1: Piqray (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced or metastatic breast cancer after disease progression following a CDK4/6 inhibitors in combination with an endocrine-based regimen.
Submission Type: Initial
Tumour Type: Breast
Project Status: Pending
Call for patient/clinician input open: March 22, 2021
Call for patient/clinician input closed: May 14, 2021
Anticipated Date: April 20, 2021
Fee Schedule1: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.